In this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.
Drs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.
A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.
Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.
Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.
Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.
Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.